Evommune's analyst kept a Buy rating but cut the target from $28 to $25. Those opposing views do not report a change in Evommune's business, so this story does not change its outlook.
This is an analyst's opinion, not a report of new trial results or a company decision. The Buy rating supports confidence, but the lower target points the other way. Neither says Evommune's business changed.
Follow Evommune, Inc. (EVMN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for EVMN